Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects
Brief Summary: Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions.

The duration of the current study is 36 weeks.


Options:
A: Arm Label: Laquinimod 0.3 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: laquinimod 0.3 | Arm Label: Laquinimod 0.6 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: laquinimod 0.6 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: laquinimod 0.3; Assigned to Arm(s): Laquinimod 0.3 mg | Intervention Type: DRUG; Name: laquinimod 0.6; Assigned to Arm(s): Laquinimod 0.6 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 3.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 3.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 4.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 4.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg | Intervention Type: DRUG; Name: Ofatumumab 3mg; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.2, Cohort 4.2, Cohort 5.2 | Intervention Type: DRUG; Name: Ofatumumab 30mg; Assigned to Arm(s): Cohort 3.1, Cohort 3.2 | Intervention Type: DRUG; Name: Ofatumumab 60mg; Assigned to Arm(s): Cohort 4.1, Cohort 4.2, Cohort 5.1, Cohort 5.2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.1, Cohort 3.2, Cohort 4.1, Cohort 4.2, Cohort 5.1
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg

Answer: A